415 related articles for article (PubMed ID: 37199073)
1. Treatment patterns and cost estimations of systemic chemotherapy for pancreatic cancer in Japan: A retrospective database study.
Takumoto Y; Shibahara R; Asami H; Akazawa M
Cancer Med; 2023 Jul; 12(13):14742-14755. PubMed ID: 37199073
[TBL] [Abstract][Full Text] [Related]
2. Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX.
Kim GP; Parisi MF; Patel MB; Pelletier CL; Belk KW
Expert Rev Clin Pharmacol; 2017 May; 10(5):559-565. PubMed ID: 28286977
[TBL] [Abstract][Full Text] [Related]
3. Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Klein-Brill A; Amar-Farkash S; Lawrence G; Collisson EA; Aran D
JAMA Netw Open; 2022 Jun; 5(6):e2216199. PubMed ID: 35675073
[TBL] [Abstract][Full Text] [Related]
4. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
5. Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX.
McBride A; Bonafede M; Cai Q; Princic N; Tran O; Pelletier C; Parisi M; Patel M
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1153-1160. PubMed ID: 28795609
[TBL] [Abstract][Full Text] [Related]
6. Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.
Queck A; Elango S; Koch C; Walter D; Schmidt J; Trebicka J; Trojan J; Pession U; Finkelmeier F; Waidmann O
Oncol Res Treat; 2022; 45(3):79-87. PubMed ID: 34875671
[TBL] [Abstract][Full Text] [Related]
7. Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
Santucci J; Tacey M; Thomson B; Michael M; Wong R; Shapiro J; Jennens R; Clarke K; Pattison S; Burge M; Zielinski R; Nikfarjam M; Ananda S; Lipton L; Gibbs P; Lee B
Eur J Cancer; 2022 Oct; 174():102-112. PubMed ID: 35988408
[TBL] [Abstract][Full Text] [Related]
8. First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population.
Hatashima A; Arango MJ; Reardon J; Freeman T; Williams T; McLaughlin EM; Abushahin L
Future Oncol; 2022 Jun; 18(20):2521-2532. PubMed ID: 35579260
[TBL] [Abstract][Full Text] [Related]
9. Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
Arciero V; Luo J; Parmar A; Dai WF; Beca JM; Raphael MJ; Isaranuwatchai W; Habbous S; Tadrous M; Earle CC; Biagi JJ; Mittmann N; Arias J; Gavura S; Chan KKW
JNCI Cancer Spectr; 2022 Jul; 6(4):. PubMed ID: 35758620
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients.
Ingram MA; Lauren BN; Pumpalova Y; Park J; Lim F; Bates SE; Kastrinos F; Manji GA; Kong CY; Hur C
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1565. PubMed ID: 35122419
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china.
Cui J; Zhang X; Qu S; Wang L
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):691-697. PubMed ID: 32976031
[TBL] [Abstract][Full Text] [Related]
12. Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407).
Mizusawa J; Fukutomi A; Katayama H; Ishii H; Ioka T; Okusaka T; Ueno H; Ueno M; Ikeda M; Mizuno N; Ozaka M; Fukuda H; Furuse J;
Pancreatology; 2018 Oct; 18(7):841-845. PubMed ID: 30075908
[TBL] [Abstract][Full Text] [Related]
13. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
[TBL] [Abstract][Full Text] [Related]
14. Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
Portal A; Pernot S; Siauve N; Landi B; Lepère C; Colussi O; Rougier P; Zaanan A; Verrière B; Taieb J
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):e23-6. PubMed ID: 24559766
[TBL] [Abstract][Full Text] [Related]
15. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
[TBL] [Abstract][Full Text] [Related]
16. Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis.
Sasaki T; Kanata R; Yamada I; Matsuyama M; Ozaka M; Sasahira N
In Vivo; 2019; 33(1):271-276. PubMed ID: 30587635
[TBL] [Abstract][Full Text] [Related]
17. Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study.
Le N; Vinci A; Schober M; Krug S; Javed MA; Kohlmann T; Sund M; Neesse A; Beyer G
Digestion; 2016; 94(4):222-229. PubMed ID: 28030863
[TBL] [Abstract][Full Text] [Related]
18. Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer.
Otsu T; Inokawa Y; Takami H; Hayashi M; Kurimoto K; Tanaka N; Tanaka H; Shimizu D; Hattori N; Kanda M; Tanaka C; Nakayama G; Kodera Y
Anticancer Res; 2022 Aug; 42(8):3889-3894. PubMed ID: 35896232
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer.
Hino K; Nishina T; Numata Y; Asagi A; Inoue T; Yoshimatsu M; Sakaguchi C; Nakasya A; Nishide N; Kajiwara T; Terao T; Nadano S; Marui K; Okujima Y; Kokubu M; Imamura Y; Kanemitsu K; Koizumi M; Kumagi T; Hiasa Y; Hyodo I
Intern Med; 2022; 61(15):2255-2261. PubMed ID: 35908959
[TBL] [Abstract][Full Text] [Related]
20. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis.
Kang J; Hwang I; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Hong SM; Shin SH; Hwang DW; Song KB; Lee JH; Kim SC; Ryoo BY
Invest New Drugs; 2018 Aug; 36(4):732-741. PubMed ID: 29616439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
